MGNX - MacroGenics Inc Stock Price, Fair Value and News

15.70USD-0.53 (-3.27%)Market Closed

Market Summary

USD15.70-0.53

Market Closed

-3.27%

MGNX Alerts

1 major insider sales recently.

MGNX Stock Price

View Fullscreen

MGNX RSI Chart

MGNX Valuation

Market Cap

980.2M

Price/Earnings (Trailing)

-108.21

Price/Sales (Trailing)

16.68

Price/Free Cashflow

-12.26

MGNX Price/Sales (Trailing)

MGNX Profitability

Return on Equity

-5.94%

Return on Assets

-3.04%

Free Cashflow Yield

-8.16%

MGNX Fundamentals

MGNX Revenue

Revenue (TTM)

58.7M

Rev. Growth (Yr)

-85.33%

Rev. Growth (Qtr)

3.11%

MGNX Earnings

Earnings (TTM)

-9.1M

Earnings Growth (Yr)

-459.88%

Earnings Growth (Qtr)

-362.46%

Breaking Down MGNX Revenue

Last 7 days

-2.5%

Last 30 days

9.0%

Last 90 days

22.7%

Trailing 12 Months

136.5%

How does MGNX drawdown profile look like?

MGNX Financial Health

Current Ratio

4.48

MGNX Investor Care

Shares Dilution (1Y)

0.96%

Diluted EPS (TTM)

-0.16

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	165.3M	152.5M	121.1M	58.7M
2022	71.7M	66.9M	93.0M	151.9M
2021	108.1M	118.6M	116.0M	77.4M
2020	68.2M	77.9M	77.4M	104.9M
2019	65.1M	56.8M	54.8M	64.2M
2018	133.3M	108.9M	84.5M	60.1M
2017	108.3M	124.8M	141.3M	157.7M
2016	98.6M	96.4M	94.1M	91.9M
2015	104.4M	101.9M	98.2M	100.9M
2014	62.2M	59.1M	57.2M	47.8M
2013	53.9M	48.8M	52.9M	58.0M
2012	58.9M	60.5M	62.2M	63.8M
2011	0	0	0	57.2M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of MacroGenics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 04, 2024	peters jeffrey stuart	sold	-799,148	15.5491	-51,395	senior vp and general counsel
Apr 04, 2024	peters jeffrey stuart	acquired	204,850	4.82	42,500	senior vp and general counsel
Mar 06, 2024	peters jeffrey stuart	acquired	213,875	10.8981	19,625	senior vp and general counsel
Mar 06, 2024	peters jeffrey stuart	sold	-421,938	21.5	-19,625	senior vp and general counsel
Mar 04, 2024	spitznagel thomas	acquired	115,000	11.5	10,000	sr vp, technical ops
Mar 04, 2024	karrels james	sold	-615,000	20.5	-30,000	svp, cfo and secretary
Mar 04, 2024	risser eric blasius	sold	-813,501	19.7648	-41,159	chief operating officer
Mar 04, 2024	risser eric blasius	acquired	152,250	10.15	15,000	chief operating officer
Mar 04, 2024	spitznagel thomas	sold	-200,000	20.00	-10,000	sr vp, technical ops
Feb 26, 2024	peters jeffrey stuart	sold	-277,655	17.22	-16,124	senior vp and general counsel

Which funds bought or sold MGNX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	AMALGAMATED BANK	reduced	-67.28	-31,000	30,000	-%
Apr 23, 2024	LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA	unchanged	-	236	3,282	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	164,568	319,182	-%
Apr 18, 2024	Diversified Trust Co	added	16.00	87,598	200,633	0.01%
Apr 18, 2024	WASATCH ADVISORS LP	reduced	-23.74	2,083,940	14,566,600	0.08%
Apr 18, 2024	FARMERS & MERCHANTS INVESTMENTS INC	unchanged	-	408	1,178	-%
Apr 18, 2024	Capital Advisors, Ltd. LLC	unchanged	-	-	1,000	-%
Apr 18, 2024	Allspring Global Investments Holdings, LLC	reduced	-68.9	-205,864	186,959	-%
Apr 15, 2024	Sound Income Strategies, LLC	new	-	77,309	77,309	0.01%
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	reduced	-41.03	-28,256	261,162	0.01%

Are Funds Buying or Selling MGNX?

Are funds buying MGNX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MGNX

No. of Funds

MGNX Alerts

1 major insider sales recently.

Unveiling MacroGenics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	t. rowe price investment management, inc.	9.1%	5,639,994	SC 13G
Feb 14, 2024	armistice capital, llc	7.37%	4,572,000	SC 13G/A
Feb 14, 2024	ra capital management, l.p.	6.5%	4,053,077	SC 13G/A
Feb 13, 2024	bb biotech ag	16.0%	9,929,963	SC 13G/A
Feb 13, 2024	vanguard group inc	6.95%	4,309,394	SC 13G/A
Jan 24, 2024	blackrock inc.	9.9%	6,140,349	SC 13G/A
Oct 30, 2023	ra capital management, l.p.	6.1%	3,764,871	SC 13G
Feb 14, 2023	rtw investments, lp	0%	0	SC 13G/A
Feb 14, 2023	bb biotech ag	14.5%	8,929,963	SC 13G/A
Feb 14, 2023	armistice capital, llc	9.91%	6,092,000	SC 13G

Recent SEC filings of MacroGenics Inc

View All Filings

Date Filed	Form Type	Document
Apr 08, 2024	4	Insider Trading
Apr 08, 2024	ARS	ARS
Apr 08, 2024	DEF 14A	DEF 14A
Apr 08, 2024	DEFA14A	DEFA14A
Apr 04, 2024	144	Notice of Insider Sale Intent
Apr 03, 2024	8-K	Current Report
Mar 08, 2024	4	Insider Trading
Mar 07, 2024	10-K	Annual Report
Mar 07, 2024	8-K	Current Report
Mar 06, 2024	4	Insider Trading

Peers (Alternatives to MacroGenics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	-1.39%	-19.31%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-5.44%	-28.86%	-41.14	9.91	76.23%	61.08%
BMRN	17.2B	2.4B	5.41%	-4.57%	102.64	7.11	15.42%	18.43%
INCY	11.6B	3.7B	-9.99%	-29.65%	19.44	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-10.10%	-42.90%	-11.39	15.18	425.83%	18.94%
BBIO	4.4B	-	-14.83%	70.74%	-6.74	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-7.99%	-0.08%	-14.09	12.46	440.80%	-27.84%
ARWR	2.9B	240.7M	-16.49%	-30.64%	-9.72	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-7.01%	-17.50%	-44.6	3.76	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.67%	-6.03%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-13.72%	-45.61%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	-0.25%	294.45%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-18.06%	3.25%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	70.91%	57.98%	-0.24	2.14	-13.45%	66.37%

MacroGenics Inc News

Latest updates

MacroGenics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	3.1%	10,720	10,397	13,136	24,496	73,099	41,734	26,007	11,101	14,147	15,662	30,757	16,881	52,691	18,253	20,257	13,682	25,192	18,741	10,593	9,662	15,794
Costs and Expenses	30.9%	60,074	45,899	58,098	62,922	61,117	66,689	67,815	77,739	72,383	68,649	71,036	68,174	54,861	54,388	67,567	59,127	63,847	56,685	63,562	57,279	57,472
S&GA Expenses	1.2%	12,560	12,409	13,692	13,527	13,672	15,355	13,669	16,253	15,583	17,161	15,234	15,036	12,561	9,732	10,216	10,233	11,890	11,833	12,122	10,219	10,547
R&D Expenses	57.2%	47,351	30,131	43,229	45,872	45,654	48,191	51,744	61,438	55,853	49,823	55,780	53,121	42,300	44,656	57,351	48,894	51,957	44,852	51,440	47,060	46,925
Interest Expenses	-	-	-	774	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-362.5%	-46,072	17,554	57,469	-38,009	12,802	-24,813	-41,304	-66,443	-58,022	-52,886	-39,935	-51,272	-2,087	-36,043	-46,885	-44,724	-30,396	-44,631	-31,767	-45,017	-44,644
Net Income Margin	-137.5%	-0.15*	0.41*	0.05*	-0.55*	-0.79*	-2.05*	-3.27*	-3.03*	-2.61*	-1.26*	-1.09*	-1.26*	-	-	-	-	-	-	-	-	-
Free Cashflow	19.8%	-28,657	-35,745	-2,375	-13,192	28,927	-10,226	-50,172	-59,111	-55,684	-16,928	-47,757	-29,662	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-12.2%	298	340	306	343	280	195	218	271	335	392	426	435	379	374	328	265	313	351	384	415	332
Current Assets	-13.7%	251	291	255	289	222	148	168	218	280	335	367	375	313	310	260	195	240	276	288	335	269
Cash Equivalents	12.3%	101	90.00	109	224	109	84.00	21.00	47.00	123	191	189	218	181	202	197	93.00	126	157	180	239	220
Inventory	14.5%	1.00	1.00	1.00	1.00	1.00	1.00	3.00	5.00	4.00	4.00	6.00	6.00	-	-	-	-	-	-	-	-	-
Net PPE	-3.5%	22.00	23.00	24.00	27.00	30.00	32.00	34.00	36.00	38.00	39.00	39.00	40.00	42.00	41.00	44.00	46.00	48.00	50.00	52.00	55.00	57.00
Liabilities	-0.1%	146	146	134	234	138	72.00	76.00	93.00	96.00	101	107	85.00	83.00	83.00	80.00	75.00	82.00	96.00	89.00	94.00	89.00
Current Liabilities	9.4%	56.00	51.00	45.00	46.00	49.00	50.00	51.00	67.00	75.00	69.00	70.00	53.00	51.00	50.00	46.00	40.00	45.00	58.00	50.00	52.00	60.00
Shareholder's Equity	-21.3%	153	194	172	109	142	123	142	178	240	291	319	351	296	292	248	191	231	255	294	321	243
Retained Earnings	-4.4%	-1,102	-1,056	-1,074	-1,131	-1,093	-1,106	-1,081	-1,040	-973	-915	-863	-823	-771	-769	-733	-686	-642	-611	-567	-535	-490
Additional Paid-In Capital	0.4%	1,255	1,250	1,245	1,240	1,235	1,229	1,224	1,218	1,213	1,207	1,181	1,173	1,067	1,061	981	877	872	866	861	855	733
Shares Outstanding	0.1%	62.00	62.00	62.00	62.00	62.00	61.00	61.00	61.00	60.00	61.00	60.00	57.00	-	-	-	-	-	-	-	-	-
Float	-	323	-	-	-	181	-	-	-	1,600	-	-	-	-	-	1,500	-	-	-	830	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	20.5%	-28,037	-35,246	-2,089	-12,833	29,320	-9,422	-49,161	-57,696	-54,309	-14,795	-45,690	-29,036	-5,533	-25,677	-36,546	-44,142	-38,044	-17,388	-48,838	-30,000	-27,228
Share Based Compensation	-9.0%	4,359	4,790	4,391	4,833	4,741	5,123	5,300	5,274	5,412	6,358	6,070	5,286	5,257	5,832	5,096	4,491	5,490	5,398	4,884	3,799	4,352
Cashflow From Investing	215.8%	38,822	-33,525	-113,476	28,095	-5,788	71,946	23,039	-18,482	-13,553	-2,617	13,818	-34,257	-16,075	-43,281	41,007	10,564	7,626	-6,372	-10,120	-70,492	45,074
Cashflow From Financing	-99.5%	273	49,911	59.00	100,118	1,359	-	263	37.00	800	18,973	2,346	100,658	1,102	74,063	99,015	162	297	37.00	633	119,005	475

MGNX Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues:
Revenues	$ 58,749	$ 151,941	$ 77,447
Costs and expenses:
Cost of product sales	619	3,351	2,651
Cost of manufacturing services	7,603	4,033	0
Research and development	166,583	207,026	214,577
Selling, general and administrative	52,188	58,949	63,014
Total costs and expenses	226,993	273,359	280,242
Loss from operations	(168,244)	(121,418)	(202,795)
Gain on royalty monetization arrangement	150,930	0	0
Interest and other income	9,686	1,660	680
Interest expense	(1,430)	0	0
Net loss	(9,058)	(119,758)	(202,115)
Other comprehensive income (loss):
Unrealized gain (loss) on investments	(1)	56	(54)
Comprehensive loss	$ (9,059)	$ (119,702)	$ (202,169)
Basic and diluted net loss per common share, basic (in dollars per share)	$ (0.15)	$ (1.95)	$ (3.37)
Basic and diluted net loss per common share, diluted (in dollars per share)	$ (0.15)	$ (1.95)	$ (3.37)
Basic weighted average number of common shares outstanding (in shares)	61,929,198	61,433,124	59,944,717
Diluted weighted average number of common shares outstanding (in shares)	61,929,198	61,433,124	59,944,717
Revenue from collaborative agreements
Revenues:
Revenues	$ 28,990	$ 119,303	$ 63,294
Revenue from government agreements
Revenues:
Revenues	1,556	1,923	1,804
Product
Revenues:
Revenues	17,939	16,727	12,349
Contract Manufacturing
Revenues:
Revenues	9,833	13,988	0
RevenueFromRoyalityAgreementsMember
Revenues:
Revenues	$ 431	$ 0	$ 0

MGNX Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 100,956	$ 108,884
Marketable securities	128,849	45,462
Accounts receivable	10,367	56,222
Inventory, net	1,221	1,451
Prepaid expenses and other current assets	9,946	10,161
Total current assets	251,339	222,180
Property, equipment and software, net	21,847	29,575
Operating lease, ROU Assets	23,846	27,335
Other non current assets	1,386	1,378
Total assets	298,418	280,468
Current liabilities:
Accounts payable	6,443	4,899
Accrued expenses and other current liabilities	24,239	28,998
Deferred revenue	21,651	9,988
Lease liabilities	3,775	4,726
Total current liabilities	56,108	48,611
Deferred revenue, net of current portion	59,243	59,480
Lease liabilities, net of current portion	30,196	30,106
Other non current liabilities	258	258
Total liabilities	145,805	138,455
Stockholders' equity:
Common stock, 0.01 par value -- 125,000,000 shares authorized, 62,070,627 and 61,701,467 shares outstanding at December 31, 2023 and December 31, 2022, respectively	621	617
Additional paid-in capital	1,254,750	1,235,095
Accumulated other comprehensive loss	(6)	(5)
Accumulated deficit	(1,102,752)	(1,093,694)
Total stockholders' equity	152,613	142,013
Total liabilities and stockholders' equity	$ 298,418	$ 280,468

About MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 Ãƒâ€” CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3;Retifanlimab, an monoclonal antibody used for cancer therapeutics; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B Ãƒâ€” CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

CEO	Dr. Scott Koenig M.D., Ph.D.
WEBSITE	macrogenics.com
INDUSTRY	Biotechnology
EMPLOYEES	357

MacroGenics Inc Frequently Asked Questions

What is the ticker symbol for MacroGenics Inc? What does MGNX stand for in stocks?

MGNX is the stock ticker symbol of MacroGenics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of MacroGenics Inc (MGNX)?

As of Wed Apr 24 2024, market cap of MacroGenics Inc is 980.18 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MGNX stock?

You can check MGNX's fair value in chart for subscribers.

What is the fair value of MGNX stock?

You can check MGNX's fair value in chart for subscribers. The fair value of MacroGenics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of MacroGenics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MGNX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is MacroGenics Inc a good stock to buy?

The fair value guage provides a quick view whether MGNX is over valued or under valued. Whether MacroGenics Inc is cheap or expensive depends on the assumptions which impact MacroGenics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MGNX.

What is MacroGenics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 24 2024, MGNX's PE ratio (Price to Earnings) is -108.21 and Price to Sales (PS) ratio is 16.68. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MGNX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on MacroGenics Inc's stock?

In the past 10 years, MacroGenics Inc has provided -0.026 (multiply by 100 for percentage) rate of return.